PL2548441T3 - Kompozycja farmaceutyczna o długotrwałym przedłużonym uwalnianiu, zawierającą wodną zawiesinę bisfosfonianu - Google Patents

Kompozycja farmaceutyczna o długotrwałym przedłużonym uwalnianiu, zawierającą wodną zawiesinę bisfosfonianu

Info

Publication number
PL2548441T3
PL2548441T3 PL12186963T PL12186963T PL2548441T3 PL 2548441 T3 PL2548441 T3 PL 2548441T3 PL 12186963 T PL12186963 T PL 12186963T PL 12186963 T PL12186963 T PL 12186963T PL 2548441 T3 PL2548441 T3 PL 2548441T3
Authority
PL
Poland
Prior art keywords
bisphosphonate
pharmaceutical composition
composition containing
long term
sustained release
Prior art date
Application number
PL12186963T
Other languages
English (en)
Polish (pl)
Inventor
Jack Yongfeng Zhang
Mary Ziping Luo
Dingyuan Fei
Kevin Xie
Jie Fei Ding
Original Assignee
Amphastar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphastar Pharmaceuticals Inc filed Critical Amphastar Pharmaceuticals Inc
Publication of PL2548441T3 publication Critical patent/PL2548441T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL12186963T 2006-12-21 2007-12-13 Kompozycja farmaceutyczna o długotrwałym przedłużonym uwalnianiu, zawierającą wodną zawiesinę bisfosfonianu PL2548441T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87680006P 2006-12-21 2006-12-21
US11/768,181 US8974801B2 (en) 2006-12-21 2007-06-25 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
EP07862893A EP2120585B1 (en) 2006-12-21 2007-12-13 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
EP12186963.0A EP2548441B1 (en) 2006-12-21 2007-12-13 Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate

Publications (1)

Publication Number Publication Date
PL2548441T3 true PL2548441T3 (pl) 2015-02-27

Family

ID=39543732

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12186963T PL2548441T3 (pl) 2006-12-21 2007-12-13 Kompozycja farmaceutyczna o długotrwałym przedłużonym uwalnianiu, zawierającą wodną zawiesinę bisfosfonianu
PL07862893T PL2120585T3 (pl) 2006-12-21 2007-12-13 Kompozycja farmaceutyczna o długotrwałym przedłużonym uwalnianiu zawierająca wodną zawiesinę bisfosfonianu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07862893T PL2120585T3 (pl) 2006-12-21 2007-12-13 Kompozycja farmaceutyczna o długotrwałym przedłużonym uwalnianiu zawierająca wodną zawiesinę bisfosfonianu

Country Status (14)

Country Link
US (3) US8974801B2 (enExample)
EP (2) EP2548441B1 (enExample)
JP (1) JP5492564B2 (enExample)
CN (1) CN101616591B (enExample)
BR (1) BRPI0720605A2 (enExample)
CA (1) CA2673058C (enExample)
DK (2) DK2120585T3 (enExample)
ES (2) ES2396733T3 (enExample)
MX (1) MX2009006447A (enExample)
PL (2) PL2548441T3 (enExample)
PT (2) PT2120585E (enExample)
RU (1) RU2453316C2 (enExample)
SI (1) SI2120585T1 (enExample)
WO (1) WO2008085281A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
AU2010330909B2 (en) 2009-12-18 2014-09-11 Howmedica Osteonics Corp. Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same
CN102453050B (zh) * 2010-11-03 2015-01-07 成都云克药业有限责任公司 一种二膦酸化合物及其制备方法
ES2714701T3 (es) 2010-11-10 2019-05-29 Stryker European Holdings I Llc Proceso para la preparación de una espuma ósea polimérica
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2013175385A1 (en) 2012-05-20 2013-11-28 Bar-Ilan Research And Development Company Ltd. Bisphosphonates vinylic monomers and polymers and uses thereof
US9492268B2 (en) 2012-11-13 2016-11-15 The Secant Group, Llc Tapered tubular implant formed from woven fabric
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN108815117A (zh) * 2018-08-23 2018-11-16 宁波蒙曼生物科技有限公司 一种镇痛药物组合物及其制备方法
CN109930209B (zh) * 2019-03-07 2022-02-15 华南理工大学 一种具高结晶度及长径比双膦酸盐晶体及其制备方法
CN112707934A (zh) * 2020-12-30 2021-04-27 华南理工大学 一种阿仑膦酸钙配合物及其制备方法
CN114349786B (zh) * 2021-12-28 2023-07-11 中国科学院上海硅酸盐研究所 阿仑膦酸钙超长纳米线及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356887A (en) 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
WO1995008304A1 (en) * 1993-09-21 1995-03-30 The Penn State Research Foundation Bone substitute composition comprising hydroxyapatite and a method of production therefor
US5462932A (en) 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP1028712B1 (en) 1997-09-19 2005-01-12 Shire Laboratories Inc. Solid solution beadlet
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
WO1999067809A1 (en) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
KR100492110B1 (ko) * 2000-05-05 2005-06-02 에프. 호프만-라 로슈 아게 비스포스폰산 또는 그의 염을 포함하는 피하 투여용겔-유사 약학 조성물
US6350471B1 (en) 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
JP4161031B2 (ja) 2000-10-31 2008-10-08 独立行政法人産業技術総合研究所 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
FR2836681B1 (fr) 2002-03-04 2004-06-18 Centre Nat Rech Scient Compose phosphocalcique modifie, composition injectable le contenant
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
JP2007501241A (ja) 2003-08-06 2007-01-25 ローディア インコーポレイティド 骨成長を促進する方法
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation

Also Published As

Publication number Publication date
EP2120585A4 (en) 2011-11-23
PL2120585T3 (pl) 2013-03-29
PT2120585E (pt) 2013-01-15
US20150157650A1 (en) 2015-06-11
EP2548441B1 (en) 2014-08-27
PT2548441E (pt) 2014-11-27
EP2120585A1 (en) 2009-11-25
RU2009128023A (ru) 2011-01-27
EP2120585B1 (en) 2012-10-03
CA2673058A1 (en) 2008-07-17
ES2524690T3 (es) 2014-12-11
BRPI0720605A2 (pt) 2014-04-08
US8974801B2 (en) 2015-03-10
SI2120585T1 (sl) 2013-05-31
RU2453316C2 (ru) 2012-06-20
CN101616591B (zh) 2014-06-18
CN101616591A (zh) 2009-12-30
US20080153784A1 (en) 2008-06-26
DK2548441T3 (en) 2014-12-08
JP5492564B2 (ja) 2014-05-14
MX2009006447A (es) 2009-07-27
US20150157649A1 (en) 2015-06-11
WO2008085281A1 (en) 2008-07-17
DK2120585T3 (da) 2013-01-21
CA2673058C (en) 2015-11-24
EP2548441A1 (en) 2013-01-23
ES2396733T3 (es) 2013-02-25
JP2010513483A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
PT2548441E (pt) Composição farmacêutica de libertação sustentada de longa duração contendo suspensão aquosa de bisfosfonato
ZA201808084B (en) Pharmaceutical composition containing a tetrahydrofolic acid
FI2068839T4 (fi) Nilotinibia tai sen suolaa käsittäviä farmaseuttisia koostumuksia
ZA200900347B (en) Preparation of pharmaceutical compositions
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
IL184558A0 (en) Sustained release composition of protein drug
ZA200901553B (en) Pest control agent in form of stable suspension
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
AP2008004691A0 (en) Stable aqueous suspension
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
ZA201100635B (en) Sustained release pharmaceutical compositions comprising quetiapine
IL208325A0 (en) Stabilizing lipis compositions for oral pharmaceutical agents
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
ZA200901083B (en) Modified release pharmaceutical composition of bupropion hydrochloride
ZA200900230B (en) 4-hydroxythiobenzamide derivatives of drugs
IL201912A0 (en) Aqueous pharmaceutical composition
PT2219611E (pt) Formas farmacêuticas para libertação de compostos ativos
HU0700469D0 (en) Floatingpharmaceutical composition of sustained release containing metronidazol
ZA200706807B (en) Composition containing chitosan for sustained drug release
GB0619891D0 (en) Pharmaceutical composition of risedronate
HK1127293A (en) Pharmaceutical compositions for sustained release of phenyephrine
IL178378A0 (en) Extended release pharmaceutical compositions
GB0617340D0 (en) Anti-malarial pharmaceutical composition
GB0610058D0 (en) Stable aqueous suspension